Sony rose more than 2% and hit a new high. Institutions are optimistic about its unique positioning. SONY.US rose more than 2%, hitting a maximum of $22.67, a record high since February 2022. Sony's Japanese shares rose nearly 3% today, once again hitting a record high. In the news, Sony previously announced that for the current fiscal year that will end at the end of March next year, the expected operating profit will reach 1.31 trillion yen, about six times that of fiscal year 1999. Among them, the entertainment business is expected to contribute 60% of the overall profit, while the electronic business is no longer reported as a department alone. Yasuo Nakane, head of global technology research at Mizuho, explained that Sony has a horizontal axis in film, music, games and animation, and a vertical axis from production to distribution. The company also has electronic technology, including image sensors, cameras and software, which makes it in a unique position compared with Apple, Netflix or Samsung.Billionaire bill ackman: Watch America.As of the close of 23:00, the main domestic futures contracts fell more and rose less. No.20 rubber fell by nearly 3%, BR rubber fell by nearly 2%, and rubber, caustic soda, vegetable oil, rapeseed meal and hot coil fell by over 1%. In terms of increase, palm oil rose by nearly 1%.
US National Security Adviser Sullivan: Sweden is conducting in-depth consultations with Israel on the Syrian issue.Russian Foreign Minister: It's not the first time that Ukrainian President refused to propose a ceasefire. On December 12, local time, the Russian Foreign Ministry reported that Hungarian Foreign Minister Sergei Jardot had spoken with Russian Foreign Minister Lavrov and told Ukrainian President Zelensky that he had rejected the Hungarian proposal for a temporary ceasefire and an exchange of prisoners of war in the Russian-Ukrainian conflict. Lavrov said that this is not the first time that the Ukrainian authorities rejected the relevant suggestions made by other countries after releasing their own signals. Hungarian Prime Minister Orban said on the 11th local time that Ukrainian President Zelensky explicitly rejected the proposal of a ceasefire on December 25th. "Hungary's rotating presidency of the European Union has come to an end. We have made the latest efforts for peace and proposed a ceasefire on December 25th and a large-scale exchange of prisoners of war. Zelensky explicitly rejected and ruled out this possibility ".US Secretary of State Blinken: Turkish interests in Syria focus on combating terrorism; Key external participants should not trigger new conflicts.
European Central Bank President Lagarde: The neutral interest rate may be slightly higher than before. European Central Bank President Lagarde said that as it gradually approaches the neutral interest rate, it will further discuss its related issues. The neutral interest rate may be slightly higher than before, and will be discussed in due course.Russian officials: The failure of sanctions against Russia to achieve geopolitical goals will cost the EU 1.5 trillion euros. On the 12th local time, Russian Deputy Foreign Minister Grushko said that Russia has adapted to various sanctions and will develop relations with all countries willing to cooperate. He said that the EU is on a road of self-destruction, and any geopolitical goal cannot be achieved through sanctions. If the EU wants to refuse cooperation with Russia, this is the EU's choice, but most assessments show that this choice has caused the EU to suffer a loss of 1.5 trillion euros.On average, the patients who won the bid from more than 6 enterprises for each drug can use the tenth batch of products won by the state in April next year. The reporter learned from the National Medical Insurance Bureau that the tenth batch of centralized drug purchase organized by the state has produced the results of the proposed bid, and 62 drugs have been successfully purchased, all of which have passed the patent period, and are produced by many enterprises and fully competitive. A total of 385 products from 234 enterprises were qualified to be selected, and on average, more than 6 enterprises of each variety planned to win the bid. In April next year, patients can use the bid-winning products after the price reduction of this centralized purchase.